Shots:
The collaboration will use Mogrify’s cellular reprogramming and bioinformatics platform to identify novel combinations of transcription factors involved in cell differentiation that can be used to generate new cochlear hair cells & increase the efficiency of direct conversion toward the target cell type in the ear
Under the terms of the agreement, Astellas is responsible for the research cost as well as providing its AAV-based genetic medicine and translational capabilities to complete experiments in pre-clinical models
The collaboration combines Astellas’ capabilities for gene therapy and research of sensorineural to develop a novel in vivo reprogramming therapy for sensorineural hearing loss
Ref: PRNewswire | Image: Astellas
